Rahaghi, Franck F.
Safdar, Zeenat
Brown, Anne Whitney
de Andrade, Joao A.
Flaherty, Kevin R.
Kaner, Robert J.
King, Christopher S.
Padilla, Maria L.
Noth, Imre
Scholand, Mary Beth
Shifren, Adrian
Nathan, Steven D.
Funding for this research was provided by:
Genentech
Article History
Received: 3 December 2019
Accepted: 3 June 2020
First Online: 14 July 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: FFR received support for the design and conduct of this study through an independent grant from Genentech, Inc. and is a consultant, speaker, and has received research funding from Actelion Pharmaceuticals US, Inc., Gilead Sciences, Inc., Lung Biotechnology, United Therapeutics Corporation, Bayer Corporation, and research funding from Bellerophon Therapeutics, Ikaria, Inc., and Eiger BioPharmaceuticals. ZS received support for the design and conduct of this study through an independent grant from Genentech, Inc. and is a consultant, speaker, and has received research funding from Actelion Pharmaceuticals US, Inc., Gilead Sciences, Inc., Lung Biotechnology, United Therapeutics Corporation, Bayer Corporation, Genetetech and Bohringer ingelheim. AWB is a consultant for Promedior, Genentech, and Theravance. She is on the speaker’s bureau for Genentech. JAD is a consultant and received research funding (to his institution) from Genentech, and Boehringer Ingelheim. He also received research funding from GBT, Medscape, Fibrogen, and the NHLBI. KRF has received personal fees from Boehringer Ingelheim, Veracyte, Roche/Genentech, Fibrogen; and research funds from Roche/Genentech, Boehringer Ingelheim. RJK is a consultant for Roche-Genentech and Boehringer-Ingelheim. He is on the speaker’s bureau for non-branded disease state lectures and has participated as an investigator in clinical trials for both Companies. CSK has served as a speaker for Genentech, Inc. He has also participated on a scientific advisory board for Boehringer Ingelheim Pharmaceuticals. MLP has served as Speaker Bureau Faculty (for non-branded IPF talks) from Genentech and serves as a Consultant for Boehringer Ingelheim. IN has served as a consultant for Genentech/HLR, Boehringer Ingelheim, Immuneworks, Sanofi Aventis, Global Blood Therapeutics. He has received research funding from Genentech and Boehringer Ingelheim. MBS has served on advisory boards, and investigator clinical trials with Genentech and Boehringer Ingelheim. MBS has patents issued for Apparatus, Compositions and Methods for Assessment of Chronic Obstructive Pulmonary Disease Progression among Rapid and Slow Decline Conditions. AS is a consultant for Roche-Genentech and Bellerophon. He is on the speaker’s bureau for Roche-Genentech and Boerhinger Ingelheim. SDN is a consultant for Roche-Genentech and Boerhinger Ingelheim. He is on the speaker’s bureau and has also received research funding from both Companies. He is also a consultant for United Therapeutics, Bellephoron, aTyr Pharma, and Galapogos.